Trials and tribulations of cell therapy for heart failure: an update on ongoing trials

• Published in: Nature reviews cardiology 2024-11
• Main Authors: Zhang, Jianyi Jay, Pogwizd, Steven M, Fukuda, Keiichi, Zimmermann, Wolfram-Hubertus, Fan, Chengming, Hare, Joshua M, Bolli, Roberto, Menasché, Philippe
• Format: Article
• Language: English
• ISSN: 1759-5002; 1759-5010; 1759-5010
• DOI: 10.1038/s41569-024-01098-8

Heart failure (HF) remains a leading cause of mortality, responsible for 13% of all deaths worldwide. The prognosis for patients with HF is poor, with only a 50% survival rate within 5 years. A major challenge of ischaemia-driven HF is the loss of cardiomyocytes, compounded by the minimal regenerative capacity of the adult heart. To date, replacement of irreversibly damaged heart muscle can only be achieved by complete heart transplantation. In the past 20 years, cell therapy has emerged and evolved as a promising avenue for cardiac repair and regeneration. During this time, cell therapy for HF has encountered substantial barriers in both preclinical studies and clinical trials but the field continues to progress and evolve from lessons learned from such research. In this Review, we provide an overview of ongoing trials of cell-based and cell product-based therapies for the treatment of HF. Findings from these trials will facilitate the clinical translation of cardiac regenerative and reparative therapies not only by evaluating the safety and efficacy of specific cell-based therapeutics but also by establishing the feasibility of novel or underexplored treatment protocols such as repeated intravenous dosing, personalized patient selection based on pharmacogenomics, systemic versus intramural cell delivery, and epicardial engraftment of engineered tissue products.